1.
J Clin Psychopharmacol
; 40(6): 641-642, 2020.
Article
in English
| MEDLINE | ID: covidwho-1840098
Subject(s)
Betacoronavirus , Chlorpromazine , Coronavirus Infections/drug therapy , Lung , Phenothiazines , Pneumonia, Viral/drug therapy , Psychotic Disorders/drug therapy , Antipsychotic Agents/pharmacokinetics , Antipsychotic Agents/therapeutic use , Betacoronavirus/drug effects , Betacoronavirus/physiology , Biological Availability , Biomedical Research , COVID-19 , Chlorpromazine/pharmacokinetics , Chlorpromazine/therapeutic use , Coronavirus Infections/metabolism , Drug Repositioning/methods , Humans , Lung/drug effects , Lung/metabolism , Maximum Allowable Concentration , Needs Assessment , Pandemics , Phenothiazines/pharmacokinetics , Phenothiazines/therapeutic use , Pneumonia, Viral/metabolism , SARS-CoV-2 , Tissue Distribution
2.
Schizophr Res
; 243: 486-488, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1586565
3.
Med Hypotheses
; 148: 110508, 2021 Mar.
Article
in English
| MEDLINE | ID: covidwho-1046208
ABSTRACT
Several studies have reported that certain psychoactive drugs could have a protective effect against SARS-CoV-2. Herein, we propose that antihistamines (anti-H1) and cationic amphiphilic drugs (CAD), specifically, have the capacity to disrupt virus entry and replication. In addition, several of these molecules have limited side effects and as such could be promising prophylactic candidates against SARS-CoV-2 infection.